🇺🇸 Pneumococcal (vaccine) in United States
2,481 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 2,481
Most-reported reactions
- Dyspnoea — 386 reports (15.56%)
- Fatigue — 284 reports (11.45%)
- Cough — 261 reports (10.52%)
- Pain — 255 reports (10.28%)
- Asthma — 250 reports (10.08%)
- Headache — 226 reports (9.11%)
- Wheezing — 215 reports (8.67%)
- Drug Ineffective — 209 reports (8.42%)
- Gastrooesophageal Reflux Disease — 201 reports (8.1%)
- Pyrexia — 194 reports (7.82%)
Other Immunology approved in United States
Frequently asked questions
Is Pneumococcal (vaccine) approved in United States?
Pneumococcal (vaccine) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pneumococcal (vaccine) in United States?
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.